Obalon Therapeutics, Inc.
If you purchased Obalon Therapeutics, Inc. securities and would like to join the action, please click "Join This Action" below.
OBALON MERGER INVESTIGATION: HALPER SADEH LLP ANNOUNCES INVESTIGATION INTO WHETHER THE MERGER OF OBALON THERAPEUTICS, INC. IS FAIR TO SHAREHOLDERS; INVESTORS ARE ENCOURAGED TO CONTACT THE FIRM – OBLN
January 21, 2021.
New York, New York—Halper Sadeh LLP, a global investor rights law firm, is investigating whether Obalon Therapeutics, Inc. (NASDAQ: OBLN) and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders in connection with the proposed merger of Obalon and ReShape Lifesciences Inc.
Under the terms of the merger agreement, existing ReShape stockholders will have majority ownership of the combined company immediately following the closing of the merger and Obalon will be renamed ReShape Lifesciences Inc. and will trade under the NASDAQ ticker symbol “RSLS.”
On behalf of Obalon shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.